JP2019533675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533675A5 JP2019533675A5 JP2019520024A JP2019520024A JP2019533675A5 JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5 JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody molecule
- tetravalent antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069848A JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408271P | 2016-10-14 | 2016-10-14 | |
| US62/408,271 | 2016-10-14 | ||
| PCT/US2017/056814 WO2018071913A2 (en) | 2016-10-14 | 2017-10-16 | Modular tetrameric bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Division JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533675A JP2019533675A (ja) | 2019-11-21 |
| JP2019533675A5 true JP2019533675A5 (https=) | 2020-11-26 |
| JP7269167B2 JP7269167B2 (ja) | 2023-05-08 |
Family
ID=60327374
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520024A Active JP7269167B2 (ja) | 2016-10-14 | 2017-10-16 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2023069848A Active JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Active JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200017588A1 (https=) |
| EP (1) | EP3526257A2 (https=) |
| JP (3) | JP7269167B2 (https=) |
| CN (2) | CN120795163A (https=) |
| AU (2) | AU2017341936B2 (https=) |
| CA (1) | CA3038504A1 (https=) |
| WO (1) | WO2018071913A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001262A2 (pt) * | 2016-07-22 | 2019-05-07 | Dana-Farber Cancer Institute, Inc. | anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos |
| EP3576793A4 (en) * | 2017-02-06 | 2021-03-31 | Dana Farber Cancer Institute, Inc. | COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING |
| JP7575100B2 (ja) * | 2018-11-13 | 2024-10-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫細胞活性化のための二重特異性抗体 |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| EP4069294A4 (en) * | 2019-12-02 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| JP2024541476A (ja) | 2021-11-24 | 2024-11-08 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｃｔｌａ－４に対する抗体及びその使用方法 |
| CA3245541A1 (en) | 2022-03-09 | 2023-09-14 | Dana-Farber Cancer Institute, Inc. | GENETICALLY MODIFIED B LYMPHOCYTES AND ASSOCIATED METHODS OF USE |
| AU2023324669A1 (en) | 2022-08-15 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| EP4572785A1 (en) | 2022-08-15 | 2025-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
| AU2024313549A1 (en) * | 2023-06-20 | 2025-10-30 | Denali Therapeutics Inc. | Dual transporters and methods of use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| JP2005518336A (ja) * | 2001-06-26 | 2005-06-23 | イムクローン システムズ インコーポレイティド | Ｖｅｇｆ受容体に結合する二重特異性抗体 |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005060520A2 (en) | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
| EP1695093A1 (en) * | 2003-12-05 | 2006-08-30 | multimmune GmbH | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| US8466263B2 (en) | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
| RU2010127156A (ru) | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| BRPI0905987A2 (pt) * | 2008-02-22 | 2015-06-30 | Dow Global Technologies Inc | Sistema de material para armazenamento de energia térmica, método para fabricar um sistema de material para armazenamento de energia térmica e uso de um sistema de material para armazenamento de energia térmica |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| WO2013096346A1 (en) * | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| CN104011080B (zh) * | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP3511343A1 (en) | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| PT2850106T (pt) * | 2012-05-18 | 2022-07-18 | Aptevo Res & Development Llc | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| CA2891764A1 (en) * | 2012-11-19 | 2014-05-22 | Baliopharm Ag | Recombinant bispecific antibody binding to cd20 and cd95 |
| CN105530959B (zh) * | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| MX367668B (es) | 2013-03-15 | 2019-08-30 | Dana Farber Cancer Inst Inc | Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos. |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| EP4043489A1 (en) | 2014-03-19 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| KR20160145813A (ko) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| PE20170441A1 (es) * | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| EP3204418B1 (en) | 2014-10-06 | 2020-03-25 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| KR102668588B1 (ko) | 2015-04-08 | 2024-05-22 | 다나-파버 캔서 인스티튜트 인크. | 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법 |
| CA3119644A1 (en) * | 2018-11-30 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
-
2017
- 2017-10-16 CN CN202510732184.9A patent/CN120795163A/zh active Pending
- 2017-10-16 JP JP2019520024A patent/JP7269167B2/ja active Active
- 2017-10-16 EP EP17798026.5A patent/EP3526257A2/en active Pending
- 2017-10-16 US US16/340,878 patent/US20200017588A1/en not_active Abandoned
- 2017-10-16 CA CA3038504A patent/CA3038504A1/en active Pending
- 2017-10-16 WO PCT/US2017/056814 patent/WO2018071913A2/en not_active Ceased
- 2017-10-16 CN CN201780067582.7A patent/CN110214152B/zh active Active
- 2017-10-16 AU AU2017341936A patent/AU2017341936B2/en active Active
-
2023
- 2023-04-21 JP JP2023069848A patent/JP7796079B2/ja active Active
-
2025
- 2025-01-31 AU AU2025200665A patent/AU2025200665A1/en active Pending
- 2025-07-16 JP JP2025119440A patent/JP2025142045A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533675A5 (https=) | ||
| JP2025142045A5 (https=) | ||
| JP2023518134A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| Holliger et al. | Engineered antibody fragments and the rise of single domains | |
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| JP2023505318A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2019514361A5 (https=) | ||
| FI3334765T3 (fi) | Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| IL262321B1 (en) | Compositions and methods for selective protein expression | |
| CA3146019A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2018525033A5 (https=) | ||
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| JP2022523710A5 (https=) | ||
| JP2024511423A5 (https=) | ||
| JP2024504162A5 (https=) | ||
| JP2018537076A5 (https=) | ||
| JP2019512207A5 (https=) | ||
| CN115667317A (zh) | 全人源的靶向cd19和cd22双特异抗原嵌合受体及其应用 | |
| CN115066274A (zh) | 三价结合分子 | |
| JP2022527081A5 (https=) | ||
| JP2023514232A5 (https=) | ||
| JP2023524102A5 (https=) | ||
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer |